methyl (S)-2-((2S,6R)-2,6-dimethylmorpholino)-3-(N-(4-(p-tolyloxy)phenyl)methylsulfonamido)propanoate | 1122477-32-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl (S)-2-((2S,6R)-2,6-dimethylmorpholino)-3-(N-(4-(p-tolyloxy)phenyl)methylsulfonamido)propanoate
• CAS: 1122477-32-0
• 化学式: C₂₄H₃₂N₂O₆S
• 分子量: 476.594
• InChiKey: PADDOEAWPATRFH-YYDVJCTNSA-N

物化性质

• 沸点：
  597.8±60.0 °C(predicted)
• 密度：
  1.219±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  33.0
• 可旋转键数：
  8.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  85.38
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  methyl (S)-2-((2S,6R)-2,6-dimethylmorpholino)-3-(N-(4-(p-tolyloxy)phenyl)methylsulfonamido)propanoate 在 盐酸羟胺 、 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 (S)-2-(cis-2,6-dimethylmorpholino)-N-hydroxy-3-(N-(4-(p-tolyloxy)phenyl)methan-2-ylsulfonamido)propanamide
  参考文献：
  名称：

  β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 2. Optimization of α-amino substituents

  摘要：

  The introduction and the optimization of an alpha-amino substituent based on a series of alpha-hydroxy-beta-N-biaryl ether sulfonamide hydroxamates is described. The modification leads to a new series of MMP-2/MMP-9 inhibitors with enhanced inhibitory activities and improved ADME properties. An efficacy study on reducing the ischemia-induced brain edema in the rat transient middle cerebral artery occlusion (tMCAo) model is also demonstrated. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.129
• 作为产物：
  描述：

  methyl (R)-3-(N-(4-(p-tolyloxy)phenyl)methylsulfonamido)-2-(((trifluoromethyl)sulfonyl)oxy)propanoate 、 cis-2,6-dimethylmorpholine 以 二氯甲烷 为溶剂， 生成 methyl (S)-2-((2S,6R)-2,6-dimethylmorpholino)-3-(N-(4-(p-tolyloxy)phenyl)methylsulfonamido)propanoate
  参考文献：
  名称：

  β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 2. Optimization of α-amino substituents

  摘要：

  The introduction and the optimization of an alpha-amino substituent based on a series of alpha-hydroxy-beta-N-biaryl ether sulfonamide hydroxamates is described. The modification leads to a new series of MMP-2/MMP-9 inhibitors with enhanced inhibitory activities and improved ADME properties. An efficacy study on reducing the ischemia-induced brain edema in the rat transient middle cerebral artery occlusion (tMCAo) model is also demonstrated. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.129